Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. reports a Schedule 13G/A showing Deep Track-affiliated holders beneficially own 6,274,076 shares of common stock. The filing states this equals 7.94% of the class based on March 2, 2026 outstanding shares of 79,050,395. The joint filing names Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin and indicates shared voting and dispositive power over the reported shares.
CorMedix Inc. reported strong first-quarter 2026 results, with net revenue of $127.4 million and net income of $38.6 million. Adjusted EBITDA reached $70.0 million, reflecting profitability after integrating the Melinta acquisition.
DefenCath generated $97.5 million of net revenue, helped by higher outpatient dialysis use and a one-time $9.0 million favorable change in sales allowance estimates, while the acquired Melinta portfolio contributed $29.9 million. The company raised full-year 2026 guidance to $325–$345 million in net revenue and $115–$135 million in adjusted EBITDA.
CorMedix also highlighted positive Phase III topline results from the ReSPECT trial of REZZAYO for prophylaxis in allogeneic stem cell transplant patients and progress in a Phase 3 taurolidine/heparin study in TPN patients. Cash and short-term investments were $178.1 million as of March 31, 2026, supporting continued growth investments.
CorMedix Inc. (CRMD) is asking stockholders to approve nine proposals at its June 23, 2026 virtual annual meeting while highlighting a strong 2025. The company reported $311.7 million in 2025 revenue, including $258.8 million from DefenCath and $52.9 million from the legacy Melinta portfolio, and turned a prior-year loss into $163.0 million in net income, or $2.04 per diluted share.
Management emphasizes the 2025 acquisition of Melinta Therapeutics, which added a diversified hospital-focused portfolio including MINOCIN, REZZAYO, VABOMERE, ORABACTIV, BAXDELA, KIMYRSA and TOPROL‑XL, and expanded the commercial footprint ahead of anticipated reimbursement changes for DefenCath in 2026. Stockholders are asked to elect seven directors, approve say‑on‑pay and auditor ratification, and vote on multiple governance and charter changes.
Key governance items include ratifying historical amendments to preferred stock certificates of designation, adopting technical charter clean‑ups, establishing class‑based voting so only affected preferred holders vote on amendments solely impacting their series, designating Delaware and federal courts as exclusive forums for certain claims, and expanding officer exculpation consistent with recent Delaware law to aid recruitment and retention. An adjournment proposal would allow extra time to gather votes on select charter and ratification items.
CorMedix Therapeutics furnished an update on its Phase III ReSPECT trial of REZZAYO (rezafungin) in adults undergoing allogeneic stem cell transplantation. The study met its primary endpoint, showing non-inferiority in fungal-free survival at Day 90, with 60.7% fungal-free survival for rezafungin versus 59.0% for a standard antimicrobial regimen. Safety was comparable, with fewer toxicity-related discontinuations and a favorable profile for drug–drug interactions. CorMedix estimates a potential U.S. prophylaxis market opportunity for REZZAYO exceeding $2 billion and plans a pre-NDA meeting followed by an sNDA submission in 2H26 to seek an expanded indication.
CorMedix Inc. files a definitive proxy statement for its 2026 Annual Meeting and highlights 2025 operational results, the August 2025 acquisition of Melinta Therapeutics LLC, and several charter and governance proposals for stockholder approval.
Management reports $311.7 million total 2025 revenue, including $258.8 million in DefenCath net sales and $52.9 million from the partial-year Melinta portfolio, and $163.0 million net income ($2.04 per diluted share). The virtual Annual Meeting is scheduled for June 23, 2026 with record date April 24, 2026. Key proposals include ratification of certain preferred-stock certificate amendments, charter technical updates, a class-voting change, exclusive-forum designation, officer liability updates, director elections, say-on-pay, auditor ratification and an adjournment proposal.
CorMedix Inc: The Vanguard Group filed an amendment to its Schedule 13G reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group now reports 0 shares and 0% ownership of CorMedix common stock as of the amendment. The filing explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Vanguard's Head of Global Fund Administration on 03/26/2026.
CorMedix Inc. furnished an updated investor presentation and reaffirmed its prior guidance that full-year 2027 DefenCath sales are estimated at $100–$140 million, clarifying an inadvertent reference to $100–$125 million on a recent earnings call. The presentation outlines a broader growth plan, including 2026 revenue guidance of $300–$320 million and adjusted EBITDA of $100–$125 million, driven by DefenCath and a diversified anti-infective portfolio. Pro forma 2025 net revenue is shown at $401 million, with Q4 2025 DefenCath sales of $91 million and 79.1 million common shares outstanding as of December 31, 2025. CorMedix also highlights late-stage expansion opportunities for DefenCath in total parenteral nutrition and for REZZAYO in fungal prophylaxis, alongside a cash and short-term investment balance of $149 million.
CorMedix Inc. reports a transformational 2025, moving to net income of $163.1 million from a $17.9 million loss in 2024, while carrying an accumulated deficit of $176.6 million as of December 31, 2025.
Growth is led by DefenCath, its first-in-class antimicrobial catheter lock, launched across U.S. hemodialysis settings in 2024 and now the largest contributor to net sales. The August 2025 acquisition of Melinta Therapeutics adds six marketed hospital anti-infectives plus cardiovascular drug TOPROL-XL, creating a broader acute-care portfolio.
DefenCath benefits from Medicare NTAP and ESRD TDAPA, but reimbursement will reset as NTAP ends in November 2026 and TDAPA shifts to a post-TDAPA add-on in July 2026, which the company expects to pressure net pricing in late 2026. CorMedix is also investing in label expansion for DefenCath and REZZAYO and advancing BARDA-supported pediatric and biothreat programs while relying on third-party manufacturing and extensive intellectual property and exclusivity protections.